33 results on '"Kurdiova, T"'
Search Results
2. Adipose tissue ageing and inflammation in COPD: obesity versus cachexia: T1:OS4.1
- Author
-
Ukropcova, B, Skyba, P, Pobeha, P, Kurdiova, T, Joppa, P, Klimes, I, Tkac, I, Ukropec, J, Gasperikova, D, and Tkacova, R
- Published
- 2010
3. Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial
- Author
-
de Courten, B, Jakubova, M, de Courten, MP, Kukurova, IJ, Vallova, S, Krumpolec, P, Valkovic, L, Kurdiova, T, Garzon, D, Barbaresi, S, Teede, HJ, Derave, W, Krssak, M, Aldini, G, Ukropec, J, and Ukropcova, B
- Abstract
Carnosine is a naturally present dipeptide in humans and an over-the counter food additive. Evidence from animal studies supports the role for carnosine in the prevention and treatment of diabetes and cardiovascular disease, yet there is limited human data. This study investigated whether carnosine supplementation in individuals with overweight or obesity improves diabetes and cardiovascular risk factors.In a double-blind randomized pilot trial in nondiabetic individuals with overweight and obesity (age 43 ± 8 years; body mass index 31 ± 4 kg/m(2) ), 15 individuals were randomly assigned to 2 g carnosine daily and 15 individuals to placebo for 12 weeks. Insulin sensitivity and secretion, glucose tolerance (oral glucose tolerance test), blood pressure, plasma lipid profile, skeletal muscle ((1) H-MRS), and urinary carnosine levels were measured.Carnosine concentrations increased in urine after supplementation (P
- Published
- 2018
4. Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial.
- Author
-
Derave W., Krssak M., Ukropcova B., Ukropec J., Aldini G., De Courten B., Jakubova M., De Courten M.P.J., Kukurova I.J., Vallova S., Krumpolec P., Valkovic L., Kurdiova T., Garzon D., Barbaresi S., Teede H.J., Derave W., Krssak M., Ukropcova B., Ukropec J., Aldini G., De Courten B., Jakubova M., De Courten M.P.J., Kukurova I.J., Vallova S., Krumpolec P., Valkovic L., Kurdiova T., Garzon D., Barbaresi S., and Teede H.J.
- Abstract
Objective Carnosine is a naturally present dipeptide in humans and an over-the counter food additive. Evidence from animal studies supports the role for carnosine in the prevention and treatment of diabetes and cardiovascular disease, yet there is limited human data. This study investigated whether carnosine supplementation in individuals with overweight or obesity improves diabetes and cardiovascular risk factors. Methods In a double-blind randomized pilot trial in nondiabetic individuals with overweight and obesity (age 43 +/- 8 years; body mass index 31 +/- 4 kg/m2), 15 individuals were randomly assigned to 2 g carnosine daily and 15 individuals to placebo for 12 weeks. Insulin sensitivity and secretion, glucose tolerance (oral glucose tolerance test), blood pressure, plasma lipid profile, skeletal muscle (1H-MRS), and urinary carnosine levels were measured. Results Carnosine concentrations increased in urine after supplementation (P < 0.05). An increase in fasting insulin and insulin resistance was hampered in individuals receiving carnosine compared to placebo, and this remained significant after adjustment for age, sex, and change in body weight (P = 0.02, P = 0.04, respectively). Two-hour glucose and insulin were both lower after carnosine supplementation compared to placebo in individuals with impaired glucose tolerance (P < 0.05). Conclusions These pilot intervention data suggest that carnosine supplementation may be an effective strategy for prevention of type 2 diabetes.Copyright © 2016 The Obesity Society.
- Published
- 2016
5. Brown adipose tissue in deep cervical fat of adult ENT patients
- Author
-
Varga, L, Stefanicka, P, Balaz, M, Kurdiova, T, Profant, M, Ukropcova, B, Ukropec, J, Varga, L, Stefanicka, P, Balaz, M, Kurdiova, T, Profant, M, Ukropcova, B, and Ukropec, J
- Published
- 2016
6. P02-54 Prediabetes in adult growth hormone deficiency is associated with a substantial reduction in serum and adipose tissue expression levels of zinc-α2-glycoprotein
- Author
-
Balaz, M., primary, Ukropcova, B., additional, Kurdiova, T., additional, Penesova, A., additional, Skyba, P., additional, Belan, V., additional, Klimes, I., additional, Payer, J., additional, Imrich, R., additional, Smith, S.R., additional, Tkacova, R., additional, Gasperikova, D., additional, and Ukropec, J., additional
- Published
- 2012
- Full Text
- View/download PDF
7. Effects of Hypoxia on Adipose Tissue Expression of NFκB, IκBα, IKKγ and IKAP in Patients with Chronic Obstructive Pulmonary Disease
- Author
-
Tkacova, R., primary, Ukropec, J., additional, Skyba, P., additional, Ukropcova, B., additional, Pobeha, P., additional, Kurdiova, T., additional, Joppa, P., additional, Klimes, I., additional, Tkac, I., additional, and Gasperikova, D., additional
- Published
- 2012
- Full Text
- View/download PDF
8. Growth hormone deficiency and rhGH-therapy to individuals with low IGF-1 levels contribute to the regulation of STAMP2 gene in subcutaneous adipose tissue
- Author
-
Ukropcova, B., Kurdiova, T., Penesova, A., Radikova, Z., Vlcek, M., Imrich, R., Štefan Zorad, Pura, M., Vanuga, P., Belan, V., Payer, J., Smith, S. R., Ukropec, J., Klimes, I., and Gasperikova, D.
9. Skeletal muscle mitochondrial cytochrome c oxidase activity is reduced in obese prediabetic individuals
- Author
-
Kurdiova, T., Ukropcova, B., Miroslav Balaz, Vician, M., Vlcek, M., Srbecky, M., Olejnik, J., Imrich, R., Belan, V., Klimes, I., Gasperikova, D., and Ukropec, J.
10. Skeletal muscle expression profile of selected pro-inflammatory myokines in obesity and type 2 diabetes
- Author
-
Maderova, D., Kurdiova, T., Miroslav Balaz, Vician, M., Belan, V., Ukropec, J., and Ukropcova, B.
11. Prediabetes and type 2 diabetes are associated with increased content of dipeptide carnosine in human skeletal muscle
- Author
-
Kurdiova, T., Decourten, B., Vallova, S., Balaz, M., Vician, M., Vlcek, M., Belan, V., Klimes, I., Gasperikova, D., Wim Derave, Ukropec, J., and Ukropcova, B.
12. MiR-494 is regulated by exercise in obese sedentary individuals with increased risk of type 2 diabetes and modulates skeletal muscle lipid metabolism in vitro
- Author
-
Miroslav Balaz, Kurdiova, T., Vician, M., Kyselovicova, O., Belan, V., Jelok, I., Wolfrum, C., Ukropec, J., and Ukropcova, B.
13. Specific changes in plasma lipidome in obesity and type 2 diabetes are associated with physical inactivity and muscle mitochondrial function
- Author
-
Kurdiova, T., Ukropcova, B., Balaz, M., Liebisch, G., Vician, M., Vlcek, M., Srbecky, M., Olejnik, J., Imrich, R., Belan, V., Klimes, I., Schmitz, G., Gasperikova, D., and Jozef Ukropec
14. Brown adipose tissue in deep cervical fat of adult ENT patients.
- Author
-
Varga, L., Stefanicka, P., Balaz, M., Kurdiova, T., Brisakova, E., Janakova, Z., Profant, M., Ukropcova, B., and Ukropec, J.
- Abstract
The article discusses research which examined and characterized the brown adipose tissue (BAT) in the cervical region of adult ear, nose and throat (ENT) patients undergoing elective surgery.
- Published
- 2016
15. Serum Afamin a Novel Marker of Increased Hepatic Lipid Content.
- Author
-
Kurdiova T, Balaz M, Kovanicova Z, Zemkova E, Kuzma M, Belan V, Payer J, Gasperikova D, Dieplinger H, Ukropcova B, and Ukropec J
- Subjects
- Adult, Body Mass Index, Cross-Sectional Studies, Diabetes Mellitus, Type 2 blood, Fatty Liver blood, Female, Follow-Up Studies, Humans, Insulin Resistance, Lipid Metabolism, Male, Prediabetic State blood, Prognosis, Serum Albumin, Human, Adiposity, Biomarkers blood, Carrier Proteins blood, Diabetes Mellitus, Type 2 diagnosis, Fatty Liver diagnosis, Glycoproteins blood, Obesity physiopathology, Prediabetic State diagnosis
- Abstract
Aim: Afamin is a liver-produced glycoprotein, a potential early marker of metabolic syndrome. Here we investigated regulation of afamin in a course of the metabolic disease development and in response to 3-month exercise intervention., Methods: We measured whole-body insulin sensitivity (euglycemic hyperinsulinemic clamp), glucose tolerance, abdominal adiposity, hepatic lipid content (magnetic resonance imaging/spectroscopy), habitual physical activity (accelerometers) and serum afamin (enzyme-linked immunosorbent assay) in 71 middle-aged men with obesity, prediabetes and newly diagnosed type 2 diabetes. Effects of 3-month exercise were investigated in 22 overweight-to-obese middle-aged individuals (16M/6F)., Results: Prediabetes and type 2 diabetes, but not obesity, were associated with increased serum afamin (p<0.001). Afamin correlated positively with hepatic lipids, fatty liver index and liver damage markers; with parameters of adiposity (waist circumference, %body fat, adipocyte diameter) and insulin resistance (fasting insulin, C-peptide, HOMA-IR; p<0.001 all). Moreover, afamin negatively correlated with whole-body insulin sensitivity (M-value/Insulin, p<0.001). Hepatic lipids and fasting insulinemia were the most important predictors of serum afamin, explaining >63% of its variability. Exercise-related changes in afamin were paralleled by reciprocal changes in insulinemia, insulin resistance and visceral adiposity. No significant change in hepatic lipid content was observed., Conclusions: Subjects with prediabetes and type 2 diabetes had the highest serum afamin levels. Afamin was more tightly related to hepatic lipid accumulation, liver damage and insulin resistance than to obesity., Competing Interests: Author VB was employed by the company Pro Diagnostic Group. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Kurdiova, Balaz, Kovanicova, Zemkova, Kuzma, Belan, Payer, Gasperikova, Dieplinger, Ukropcova and Ukropec.)
- Published
- 2021
- Full Text
- View/download PDF
16. Author Correction: Effect of carnosine supplementation on the plasma lipidome in overweight and obese adults: a pilot randomised controlled trial.
- Author
-
Baye E, Ukropec J, de Courten MPJ, Vallova S, Krumpolec P, Kurdiova T, Aldini G, Ukropcova B, and de Courten B
- Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
- Full Text
- View/download PDF
17. Carnosine supplementation reduces plasma soluble transferrin receptor in healthy overweight or obese individuals: a pilot randomised trial.
- Author
-
Baye E, Ukropec J, de Courten MPJ, Kurdiova T, Krumpolec P, Fernández-Real JM, Aldini G, Ukropcova B, and de Courten B
- Subjects
- Adult, Biomarkers blood, Blood Glucose metabolism, Carnosine pharmacology, Chelating Agents pharmacology, Female, Ferritins blood, Humans, Insulin Resistance, Male, Middle Aged, Obesity blood, Overweight blood, Pilot Projects, Transferrin metabolism, Carnosine administration & dosage, Chelating Agents administration & dosage, Dietary Supplements, Iron blood, Obesity drug therapy, Overweight drug therapy, Receptors, Transferrin blood
- Abstract
Abnormalities of iron homeostasis have been linked to insulin resistance, type 2 diabetes and cardiovascular disease. Carnosine, an over-the-counter food supplement with chelating properties, has been shown to decrease serum iron and improve glucose metabolism in diabetic rodents. We have previously demonstrated that carnosine supplementation prevented worsening of glucose metabolism in healthy overweight and obese middle-aged adults. Yet, the impact of carnosine on markers of iron metabolism in humans has not been investigated. We aimed to determine whether carnosine supplementation has an effect on iron parameters in overweight and obese, otherwise healthy adults. We included 26 participants, who were randomly allocated to receive 1 g carnosine (n = 14) or identical placebo (n = 12) twice daily for 12 weeks. Iron parameters including iron, ferritin, transferrin, soluble transferrin receptor, total iron binding capacity and iron saturation were measured in serum or plasma by standard commercial assays. Carnosine supplementation decreased plasma soluble transferrin receptor compared to placebo (mean change difference ± standard error: - 0.07 ± 0.03 mg/l, p = 0.04). None of the other iron parameters were different between carnosine and placebo groups. At follow-up, soluble transferrin receptor was associated inversely with urinary carnosine concentrations and positively with serum carnosinase-1 activity (both p < 0.02). Our findings suggest that carnosine may modulate iron metabolism in high-risk groups which could ameliorate insulin resistance and prevent type 2 diabetes. Larger human clinical trials are required to confirm our results.
- Published
- 2019
- Full Text
- View/download PDF
18. Carnosine Supplementation Improves Serum Resistin Concentrations in Overweight or Obese Otherwise Healthy Adults: A Pilot Randomized Trial.
- Author
-
Baye E, Ukropec J, de Courten MPJ, Mousa A, Kurdiova T, Johnson J, Wilson K, Plebanski M, Aldini G, Ukropcova B, and de Courten B
- Subjects
- Adult, Biomarkers blood, Double-Blind Method, Down-Regulation, Female, Humans, Male, Middle Aged, Obesity blood, Obesity diagnosis, Pilot Projects, Slovakia, Treatment Outcome, Carnosine administration & dosage, Dietary Supplements, Obesity therapy, Resistin blood
- Abstract
Adipokines play an important role in the regulation of glucose metabolism. We have previously shown that carnosine supplementation in overweight or obese non-diabetic individuals improves glucose metabolism but does not change adiponectin concentrations. However, its effect on other adipokines has not been investigated. Herein we further determined the effect of carnosine supplementation on serum adipsin, resistin and leptin. Twenty-two overweight or obese otherwise healthy adults were randomly assigned to receive either 2 g of carnosine ( n = 13) or identically looking placebo ( n = 9) for 12 weeks. Serum adipsin, leptin and resistin were analyzed using a bead-based multiplex assay. Carnosine supplementation decreased serum resistin concentrations compared to placebo (mean change from baseline: -35 ± 83 carnosine vs. 35 ± 55 ng/mL placebo, p = 0.04). There was a trend for a reduction in serum leptin concentrations after carnosine supplementation (-76 ± 165 ng/mL carnosine vs. 20 ± 28 ng/mL placebo, p = 0.06). The changes in leptin and resistin concentrations were inversely related to the change in concentration for urinary carnosine ( r = -0.72, p = 0.0002; r = -0.67, p = 0.0009, respectively), carnosine-propanal ( r = -0.56, p = 0.005; r = -0.63, p = 0.001, respectively) and carnosine-propanol ( r = -0.61, p = 0.002; r = -0.60, p = 0.002, respectively). There were no differences between groups in change in adipsin concentrations. Our findings show carnosine supplementation may normalize some, but not all, of the serum adipokine concentrations involved in glucose metabolism, in overweight and obese individuals. Further clinical trials with larger samples are needed to confirm these results.
- Published
- 2018
- Full Text
- View/download PDF
19. Mutations in SURF1 are important genetic causes of Leigh syndrome in Slovak patients.
- Author
-
Danis D, Brennerova K, Skopkova M, Kurdiova T, Ukropec J, Stanik J, Kolnikova M, and Gasperikova D
- Subjects
- Child, Child, Preschool, Female, Humans, Infant, Leigh Disease diagnostic imaging, Leigh Disease pathology, Leigh Disease physiopathology, Male, Membrane Proteins antagonists & inhibitors, Mitochondrial Proteins antagonists & inhibitors, Mutation, Pedigree, Slovakia, Exome Sequencing, Leigh Disease genetics, Membrane Proteins genetics, Mitochondrial Proteins genetics
- Abstract
Objectives: Leigh syndrome is a progressive early onset neurodegenerative disease typically presenting with psychomotor regression, signs of brainstem and/or basal ganglia disease, lactic acidosis, and characteristic magnetic resonance imaging findings. At molecular level, deficiency of respiratory complexes and/or pyruvate dehydrogenase complex is usually observed. Nuclear gene SURF1 encodes an assembly factor for cytochrome c-oxidase complex of the respiratory chain and autosomal recessive mutations in SURF1 are one of the most frequent causes of cytochrome c-oxidase-related Leigh syndrome cases. Here, we aimed to elucidate the genetic basis of Leigh syndrome in three Slovak families., Methods and Results: Three probands presenting with Leigh syndrome were selected for DNA analysis. The first proband, presenting with atypical LS onset without abnormal basal ganglia magnetic resonance imaging findings, was analyzed with whole exome sequencing. In the two remaining probands, SURF1 was screened by Sanger sequencing. Four different heterozygous mutations were identified in SURF1: c.312_321delinsAT:p.(Pro104Profs*1), c.588+1G>A, c.823_833+7del:p. (?) and c.845_846del:p.(Ser282Cysfs*9). All the mutations are predicted to have a loss-of-function effect., Conclusions: We identified disease-causing mutations in all three probands, which points to the important role of SURF1 gene in etiology of Leigh syndrome in Slovakia. Our data showed that patients with atypical Leigh syndrome phenotype without lesions in basal ganglia may benefit from the whole exome sequencing method. In the case of probands presenting the typical phenotype, Sanger sequencing of the SURF1 gene seems to be an effective method of DNA analysis.
- Published
- 2018
- Full Text
- View/download PDF
20. Effect of carnosine supplementation on the plasma lipidome in overweight and obese adults: a pilot randomised controlled trial.
- Author
-
Baye E, Ukropec J, de Courten MP, Vallova S, Krumpolec P, Kurdiova T, Aldini G, Ukropcova B, and de Courten B
- Subjects
- Adult, Biomarkers blood, Double-Blind Method, Dyslipidemias blood, Dyslipidemias therapy, Female, Humans, Male, Pilot Projects, Treatment Outcome, Carnosine therapeutic use, Dietary Supplements, Lipids blood, Overweight blood, Overweight therapy
- Abstract
Carnosine has been shown to reduce oxidation and glycation of low density lipoprotein hence improving dyslipidaemia in rodents. The effect of carnosine on human plasma lipidome has thus far not been investigated. We aimed to determine whether carnosine supplementation improves the plasma lipidome in overweight and obese individuals. Lipid analysis was performed by liquid chromatography mass spectrometry in 24 overweight and obese adults: 13 were randomly assigned to 2 g carnosine daily and 11 to placebo, and treated for 12 weeks. Carnosine supplementation maintained trihexosylceramide (0.01 ± 0.19 vs -0.28 ± 0.34 nmol/ml, p = 0.04), phosphatidylcholine (77 ± 167 vs -81 ± 196 nmol/ml, p = 0.01) and free cholesterol (20 ± 80 vs -69 ± 80 nmol/ml, p = 0.006) levels compared to placebo. Trihexosylceramide was inversely related with fasting insulin (r = -0.6, p = 0.002), insulin resistance (r = -0.6, p = 0.003), insulin secretion (r = -0.4, p = 0.05) and serum carnosinase 1 activity (r = -0.3, p = 0.05). Both phosphatidylcholine and free cholesterol did not correlate with any cardiometabolic parameters. Our data suggest that carnosine may have beneficial effects on the plasma lipidome. Future larger clinical trials are needed to confirm this.
- Published
- 2017
- Full Text
- View/download PDF
21. EIF2S3 Mutations Associated with Severe X-Linked Intellectual Disability Syndrome MEHMO.
- Author
-
Skopkova M, Hennig F, Shin BS, Turner CE, Stanikova D, Brennerova K, Stanik J, Fischer U, Henden L, Müller U, Steinberger D, Leshinsky-Silver E, Bottani A, Kurdiova T, Ukropec J, Nyitrayova O, Kolnikova M, Klimes I, Borck G, Bahlo M, Haas SA, Kim JR, Lotspeich-Cole LE, Gasperikova D, Dever TE, and Kalscheuer VM
- Subjects
- Amino Acid Sequence, Family Health, Female, Genitalia abnormalities, Humans, Male, Mental Retardation, X-Linked pathology, Obesity, Pedigree, Sequence Analysis, DNA methods, Sequence Homology, Amino Acid, Syndrome, Epilepsy, Eukaryotic Initiation Factor-2 genetics, Hypogonadism, Intellectual Disability genetics, Mental Retardation, X-Linked genetics, Microcephaly, Mutation
- Abstract
Impairment of translation initiation and its regulation within the integrated stress response (ISR) and related unfolded-protein response has been identified as a cause of several multisystemic syndromes. Here, we link MEHMO syndrome, whose genetic etiology was unknown, to this group of disorders. MEHMO is a rare X-linked syndrome characterized by profound intellectual disability, epilepsy, hypogonadism and hypogenitalism, microcephaly, and obesity. We have identified a C-terminal frameshift mutation (Ile465Serfs) in the EIF2S3 gene in three families with MEHMO syndrome and a novel maternally inherited missense EIF2S3 variant (c.324T>A; p.Ser108Arg) in another male patient with less severe clinical symptoms. The EIF2S3 gene encodes the γ subunit of eukaryotic translation initiation factor 2 (eIF2), crucial for initiation of protein synthesis and regulation of the ISR. Studies in patient fibroblasts confirm increased ISR activation due to the Ile465Serfs mutation and functional assays in yeast demonstrate that the Ile465Serfs mutation impairs eIF2γ function to a greater extent than tested missense mutations, consistent with the more severe clinical phenotype of the Ile465Serfs male mutation carriers. Thus, we propose that more severe EIF2S3 mutations cause the full MEHMO phenotype, while less deleterious mutations cause a milder form of the syndrome with only a subset of the symptoms., (© 2017 WILEY PERIODICALS, INC.)
- Published
- 2017
- Full Text
- View/download PDF
22. Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial.
- Author
-
de Courten B, Jakubova M, de Courten MP, Kukurova IJ, Vallova S, Krumpolec P, Valkovic L, Kurdiova T, Garzon D, Barbaresi S, Teede HJ, Derave W, Krssak M, Aldini G, Ukropec J, and Ukropcova B
- Subjects
- Adult, Blood Glucose analysis, Body Weight, Diabetes Mellitus, Type 2 blood, Dietary Supplements, Double-Blind Method, Fasting, Female, Glucose Intolerance, Glucose Tolerance Test, Humans, Insulin blood, Insulin Resistance, Male, Middle Aged, Obesity blood, Overweight blood, Pilot Projects, Placebos, Risk Factors, Carnosine administration & dosage, Glucose metabolism
- Abstract
Objective: Carnosine is a naturally present dipeptide in humans and an over-the counter food additive. Evidence from animal studies supports the role for carnosine in the prevention and treatment of diabetes and cardiovascular disease, yet there is limited human data. This study investigated whether carnosine supplementation in individuals with overweight or obesity improves diabetes and cardiovascular risk factors., Methods: In a double-blind randomized pilot trial in nondiabetic individuals with overweight and obesity (age 43 ± 8 years; body mass index 31 ± 4 kg/m(2) ), 15 individuals were randomly assigned to 2 g carnosine daily and 15 individuals to placebo for 12 weeks. Insulin sensitivity and secretion, glucose tolerance (oral glucose tolerance test), blood pressure, plasma lipid profile, skeletal muscle ((1) H-MRS), and urinary carnosine levels were measured., Results: Carnosine concentrations increased in urine after supplementation (P < 0.05). An increase in fasting insulin and insulin resistance was hampered in individuals receiving carnosine compared to placebo, and this remained significant after adjustment for age, sex, and change in body weight (P = 0.02, P = 0.04, respectively). Two-hour glucose and insulin were both lower after carnosine supplementation compared to placebo in individuals with impaired glucose tolerance (P < 0.05)., Conclusions: These pilot intervention data suggest that carnosine supplementation may be an effective strategy for prevention of type 2 diabetes., (© 2016 The Obesity Society.)
- Published
- 2016
- Full Text
- View/download PDF
23. Muscle Carnosine Is Associated with Cardiometabolic Risk Factors in Humans.
- Author
-
de Courten B, Kurdiova T, de Courten MP, Belan V, Everaert I, Vician M, Teede H, Gasperikova D, Aldini G, Derave W, Ukropec J, and Ukropcova B
- Subjects
- Adult, Cholesterol, HDL blood, Glucose Tolerance Test, Humans, Insulin Resistance physiology, Magnetic Resonance Spectroscopy, Male, Middle Aged, Motor Activity physiology, Risk Factors, Carnosine metabolism, Muscle, Skeletal metabolism
- Abstract
Background: Carnosine is a naturally present dipeptide abundant in skeletal muscle and an over-the counter food additive. Animal data suggest a role of carnosine supplementation in the prevention and treatment of obesity, insulin resistance, type 2 diabetes and cardiovascular disease but only limited human data exists., Methods and Results: Samples of vastus lateralis muscle were obtained by needle biopsy. We measured muscle carnosine levels (high-performance liquid chromatography), % body fat (bioimpedance), abdominal subcutaneous and visceral adiposity (magnetic resonance imaging), insulin sensitivity (euglycaemic hyperinsulinemic clamp), resting energy expenditure (REE, indirect calorimetry), free-living ambulatory physical activity (accelerometers) and lipid profile in 36 sedentary non-vegetarian middle aged men (45±7 years) with varying degrees of adiposity and glucose tolerance. Muscle carnosine content was positively related to % body fat (r = 0.35, p = 0.04) and subcutaneous (r = 0.38, p = 0.02) but not visceral fat (r = 0.17, p = 0.33). Muscle carnosine content was inversely associated with insulin sensitivity (r = -0.44, p = 0.008), REE (r = -0.58, p<0.001) and HDL-cholesterol levels (r = -0.34, p = 0.048). Insulin sensitivity and physical activity were the best predictors of muscle carnosine content after adjustment for adiposity., Conclusion: Our data shows that higher carnosine content in human skeletal muscle is positively associated with insulin resistance and fasting metabolic preference for glucose. Moreover, it is negatively associated with HDL-cholesterol and basal energy expenditure. Intervention studies targeting insulin resistance, metabolic and cardiovascular disease risk factors are necessary to evaluate its putative role in the prevention and management of type 2 diabetes and cardiovascular disease.
- Published
- 2015
- Full Text
- View/download PDF
24. Adipokine zinc-α2-glycoprotein regulated by growth hormone and linked to insulin sensitivity.
- Author
-
Balaz M, Ukropcova B, Kurdiova T, Gajdosechova L, Vlcek M, Janakova Z, Fedeles J, Pura M, Gasperikova D, Smith SR, Tkacova R, Klimes I, Payer J, Wolfrum C, and Ukropec J
- Subjects
- Adipocytes drug effects, Adipocytes metabolism, Adipose Tissue metabolism, Administration, Oral, Adult, Aged, Case-Control Studies, Cohort Studies, Dietary Supplements, Female, Human Growth Hormone deficiency, Human Growth Hormone pharmacology, Humans, Lipid Metabolism, Male, Middle Aged, Zn-Alpha-2-Glycoprotein, Adipose Tissue drug effects, Human Growth Hormone administration & dosage, Obesity metabolism, Seminal Plasma Proteins metabolism
- Abstract
Objective: Hypertrophic obesity is associated with impaired insulin sensitivity and lipid-mobilizing activity of zinc-α2-glycoprotein. Adipose tissue (AT) of growth hormone (GH) -deficient patients is characterized by extreme adipocyte hypertrophy due to defects in AT lipid metabolism. It was hypothesized that zinc-α2-glycoprotein is regulated by GH and mediates some of its beneficial effects in AT., Methods: AT from patients with GH deficiency and individuals with obesity-related GH deficit was obtained before and after 5-year and 24-month GH supplementation therapy. GH action was tested in primary human adipocytes. Relationships of GH and zinc-α2-glycoprotein with adipocyte size and insulin sensitivity were evaluated in nondiabetic patients with noncancerous cachexia and hypertrophic obesity., Results: AT in GH-deficient adults displayed a substantial reduction of zinc-α2-glycoprotein. GH therapy normalized AT zinc-α2-glycoprotein. Obesity-related relative GH deficit was associated with almost 80% reduction of zinc-α2-glycoprotein mRNA in AT. GH increased zinc-α2-glycoprotein mRNA in both AT of obese men and primary human adipocytes. Interdependence of GH and zinc-α2-glycoprotein in regulating AT morphology and metabolic phenotype was evident from their relationship with adipocyte size and AT-specific and whole-body insulin sensitivity., Conclusions: The results demonstrate that GH is involved in regulation of AT zinc-α2-glycoprotein; however, the molecular mechanism linking GH and zinc-α2-glycoprotein in AT is yet unknown., (© 2014 The Obesity Society.)
- Published
- 2015
- Full Text
- View/download PDF
25. Improved adipose tissue metabolism after 5-year growth hormone replacement therapy in growth hormone deficient adults: The role of zinc-α2-glycoprotein.
- Author
-
Balaž M, Ukropcova B, Kurdiova T, Vlcek M, Surova M, Krumpolec P, Vanuga P, Gašperíková D, Klimeš I, Payer J, Wolfrum C, and Ukropec J
- Abstract
Growth hormone (GH) supplementation therapy to adults with GH deficiency has beneficial effects on adipose tissue lipid metabolism, improving thus adipocyte functional morphology and insulin sensitivity. However, molecular nature of these effects remains unclear. We therefore tested the hypothesis that lipid-mobilizing adipokine zinc-α2-glycoprotein is causally linked to GH effects on adipose tissue lipid metabolism. Seventeen patients with severe GH deficiency examined before and after the 5-year GH replacement therapy were compared with age-, gender- and BMI-matched healthy controls. Euglycemic hyperinsulinemic clamp was used to assess whole-body and adipose tissue-specific insulin sensitivity. Glucose tolerance was determined by oGTT, visceral and subcutaneous abdominal adiposity by MRI, adipocyte size morphometrically after collagenase digestion, lipid accumulation and release was studied in differentiated human primary adipocytes in association with GH treatment and zinc-α2-glycoprotein gene silencing. Five-year GH replacement therapy improved glucose tolerance, adipose tissue insulin sensitivity and reduced adipocyte size without affecting adiposity and whole-body insulin sensitivity. Adipose tissue zinc-α2-glycoprotein expression was positively associated with whole-body and adipose tissue insulin sensitivity and negatively with adipocyte size. GH treatment to adipocytes in vitro increased zinc-α2-glycoprotein expression (>50%) and was paralleled by enhanced lipolysis and decreased triglyceride accumulation (>35%). Moreover, GH treatment improved antilipolytic action of insulin in cultured adipocytes. Most importantly, silencing zinc-α2-glycoprotein eliminated all of the GH effects on adipocyte lipid metabolism. Effects of 5-year GH supplementation therapy on adipose tissue lipid metabolism and insulin sensitivity are associated with zinc-α2-glycoprotein. Presence of this adipokine is required for the GH action on adipocyte lipid metabolism in vitro.
- Published
- 2014
- Full Text
- View/download PDF
26. Subcutaneous adipose tissue zinc-α2-glycoprotein is associated with adipose tissue and whole-body insulin sensitivity.
- Author
-
Balaz M, Vician M, Janakova Z, Kurdiova T, Surova M, Imrich R, Majercikova Z, Penesova A, Vlcek M, Kiss A, Belan V, Klimes I, Olejnik J, Gasperikova D, Wolfrum C, Ukropcova B, and Ukropec J
- Subjects
- Adipocytes metabolism, Adiponectin genetics, Adiponectin metabolism, Adiposity genetics, Adult, Diabetes Mellitus, Type 2 metabolism, Female, Gene Expression, Gene Silencing, Glucose Transporter Type 4 genetics, Glucose Transporter Type 4 metabolism, Humans, Insulin Receptor Substrate Proteins genetics, Insulin Receptor Substrate Proteins metabolism, Male, Middle Aged, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Prediabetic State metabolism, RNA, Messenger metabolism, Seminal Plasma Proteins genetics, Transcription Factors genetics, Transcription Factors metabolism, Zn-Alpha-2-Glycoprotein, Insulin Resistance genetics, Intra-Abdominal Fat metabolism, Obesity metabolism, Seminal Plasma Proteins metabolism, Subcutaneous Fat metabolism
- Abstract
Objective: To examine the regulatory aspects of zinc-α2-glycoprotein (ZAG) association with obesity-related insulin resistance., Methods: ZAG mRNA and protein were analyzed in subcutaneous adipose tissue (AT) and circulation of lean, obese, prediabetic, and type 2 diabetic men; both subcutaneous and visceral AT were explored in lean and extremely obese. Clinical and ex vivo findings were corroborated by results of in vitro ZAG silencing experiment., Results: Subcutaneous AT ZAG was reduced in obesity, with a trend to further decrease with prediabetes and type 2 diabetes. ZAG was 3.3-fold higher in subcutaneous than in visceral AT of lean individuals. All differences were lost in extreme obesity. Obesity-associated changes in AT were not paralleled by alterations of circulating ZAG. Subcutaneous AT ZAG correlated with adiposity, adipocyte hypertrophy, whole-body and AT insulin sensitivity, mitochondrial content, expression of GLUT4, PGC1α, and adiponectin. Subcutaneous AT ZAG and adipocyte size were the only predictors of insulin sensitivity, independent on age and BMI. Silencing ZAG resulted in reduced adiponectin, IRS1, GLUT4, and PGC1α gene expression in primary human adipocytes., Conclusions: ZAG in subcutaneous, but not in visceral AT, was markedly reduced in obesity. Clinical, cellular, and molecular evidence indicate that ZAG plays an important role in modulating whole-body and AT insulin sensitivity., (Copyright © 2014 The Obesity Society.)
- Published
- 2014
- Full Text
- View/download PDF
27. Exercise-mimicking treatment fails to increase Fndc5 mRNA & irisin secretion in primary human myotubes.
- Author
-
Kurdiova T, Balaz M, Mayer A, Maderova D, Belan V, Wolfrum C, Ukropec J, and Ukropcova B
- Subjects
- Cells, Cultured, Colforsin pharmacology, Diabetes Mellitus, Type 2 genetics, Diabetes Mellitus, Type 2 metabolism, Humans, Ionomycin pharmacology, Muscle Fibers, Skeletal drug effects, Muscle, Skeletal cytology, Obesity genetics, Obesity metabolism, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Prediabetic State genetics, Prediabetic State metabolism, Transcription Factors genetics, Transcription Factors metabolism, Exercise physiology, Fibronectins genetics, Fibronectins metabolism, Muscle Fibers, Skeletal metabolism, RNA, Messenger genetics
- Abstract
Irisin, myokine secreted by skeletal muscle, was suggested to mediate some of exercise health benefits via "browning" of white adipose tissue. However, mounting evidence contradicts the regulatory role of exercise for muscle irisin production/secretion in humans. Thus, we explored the direct effect of exercise-mimicking treatment on irisin in human primary muscle cells in vitro. Human primary muscle cell cultures were established from lean, obese prediabetic and type-2-diabetic individuals. Complex metabolic phenotyping included assessment of insulin sensitivity (euglycemic hyperinsulinemic clamp) and adiposity content&distribution (MRI&MRS). In vitro exercise-mimicking treatment (forskolin+ionomycin) was delivered in 1-h pulse/day during differentiation. Fndc5 mRNA (qRT-PCR) and secreted irisin (ELISA) were determined in cells and media. Exercise-mimicking treatment more than doubled Pgc1α mRNA in differentiated muscle cells. Nevertheless, Fndc5 mRNA was reduced by 18% and irisin in media by 20%. Moreover, Fncd5 mRNA was increased in myotubes derived from individuals with type-2-diabetes, independent on exercise-mimicking treatment. Fndc5 mRNA in cells was positively related to fasting glycemia (p=0.0001) and negatively to whole-body insulin sensitivity (p<0.05). Collectively, our data do not support the role of exercise-related signaling pathways in irisin regulation in human skeletal muscle and confirm our previous observations on increased Fndc5 expression in muscle cells from individuals with type-2-diabetes., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
28. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies.
- Author
-
Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, Srbecky M, Imrich R, Kyselovicova O, Belan V, Jelok I, Wolfrum C, Klimes I, Krssak M, Zemkova E, Gasperikova D, Ukropec J, and Ukropcova B
- Subjects
- Adult, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 rehabilitation, Female, Humans, Male, Obesity complications, Obesity rehabilitation, Adipose Tissue physiopathology, Diabetes Mellitus, Type 2 physiopathology, Exercise Therapy, Fibronectins metabolism, Muscle, Skeletal physiopathology, Obesity physiopathology
- Abstract
Irisin was identified as a myokine secreted by contracting skeletal muscle, possibly mediating some exercise health benefits via 'browning' of white adipose tissue. However, a controversy exists concerning irisin origin, regulation and function in humans. Thus, we have explored Fndc5 gene and irisin protein in two clinical studies: (i) a cross-sectional study (effects of type 2 diabetes (T2D) in drug-naive men) and (ii) an intervention study (exercise effects in sedentary, overweight/obese individuals). Glucose tolerance and insulin sensitivity were assessed. Maximal aerobic capacity and muscle strength were measured before and after training. Body composition (magnetic resonance imaging), muscle and liver fat content (1H-magnetic resonance spectroscopy (MRS)) and in vivo muscle metabolism (32P-MRS) were determined. Skeletal muscle and subcutaneous abdominal adipose tissue samples were taken in the fasted state and during euglycaemic hyperinsulinaemia (adipose tissue) and before/after exercise training (muscle). We found that muscle Fndc5 mRNA was increased in prediabetes but not T2D. Fndc5 in adipose tissue and irisin in plasma were reduced in T2D by 40% and 50%, respectively. In contrast, T2D-derived myotubes expressed/secreted the highest levels of Fndc5/irisin. Neither hyperinsulinaemia (adipose tissue/plasma) nor exercise (muscle/plasma) affected Fndc5/irisin in vivo. Circulating irisin was positively associated with muscle mass, strength and metabolism and negatively with fasting glycaemia. Glucose and palmitate decreased Fndc5 mRNA in myotubes in vitro. We conclude that distinct patterns of Fndc5/irisin in muscle, adipose tissue and circulation, and concordant in vivo down-regulation in T2D, indicate that irisin might distinguish metabolic health and disease. Moreover, Fndc5/irisin was discordantly regulated in diabetic muscle and myotubes in vitro, suggesting that whole body factors, such as glucose and fatty acids, might be important for irisin regulation. Exercise did not affect Fndc5/irisin. However, irisin was positively linked to muscle mass, strength and metabolism, pointing to common regulatory factors and/or the potential for irisin to modify muscle phenotype.
- Published
- 2014
- Full Text
- View/download PDF
29. Repeated immobilization stress induces catecholamine production in rat mesenteric adipocytes.
- Author
-
Vargovic P, Ukropec J, Laukova M, Kurdiova T, Balaz M, Manz B, Ukropcova B, and Kvetnansky R
- Subjects
- Adipose Tissue, Brown metabolism, Adipose Tissue, White blood supply, Adipose Tissue, White innervation, Animals, Epinephrine metabolism, Gene Expression Regulation, Enzymologic, Male, Mesentery, Norepinephrine metabolism, Phenylethanolamine N-Methyltransferase genetics, Phenylethanolamine N-Methyltransferase metabolism, Rats, Rats, Sprague-Dawley, Stress, Psychological etiology, Stromal Cells metabolism, Subcutaneous Fat metabolism, Time Factors, Tyrosine 3-Monooxygenase genetics, Tyrosine 3-Monooxygenase metabolism, Up-Regulation, Vesicular Monoamine Transport Proteins genetics, Vesicular Monoamine Transport Proteins metabolism, Adipocytes metabolism, Adipose Tissue, White metabolism, Catecholamines metabolism, Restraint, Physical psychology, Stress, Psychological metabolism
- Abstract
Catecholamines (CATs), the major regulator of lipolysis in adipose tissue, are produced mainly by the sympathoadrenal system. However, recent studies report endogenous CAT production in adipocytes themselves. This study investigated the effects of single and repeated (7-14 times) immobilization (IMO) stress on CAT production in various fat depots of the rat. Single IMO quickly induced a rise of norepinephrine (NE) and epinephrine (EPI) concentration in mesenteric and brown adipose depots. Adaptive response to repeated IMO included robust increases of NE and EPI levels in mesenteric and subcutaneous adipose tissue. These changes likely reflect the activation of sympathetic nervous system in fat depots by IMO. However, this process was also paralleled by an increase in tyrosine hydroxylase gene expression in mesenteric fat, suggesting regulation of endogenous CAT production in adipose tissue cells. Detailed time-course analysis (time course 10, 30, and 120 min) clearly showed that repeated stress led to increased CAT biosynthesis in isolated mesenteric adipocytes resulting in gradual accumulation of intracellular EPI during IMO exposure. Comparable changes were also found in stromal/vascular fractions, with more pronounced effects of single than repeated IMO. The potential physiological importance of these findings is accentuated by parallel increase in expression of vesicular monoamine transporter 1, indicating a need for CAT storage in adipocyte vesicles. Taken together, we show that CAT production occurs in adipose tissue and may be activated by stress directly in adipocytes.
- Published
- 2013
- Full Text
- View/download PDF
30. Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease.
- Author
-
Pobeha P, Ukropec J, Skyba P, Ukropcova B, Joppa P, Kurdiova T, Javorsky M, Klimes I, Tkac I, Gasperikova D, and Tkacova R
- Subjects
- Adipose Tissue metabolism, Biomarkers blood, Bone Density, Bone Remodeling, Female, Humans, Inflammation blood, Inflammation complications, Leptin blood, Leptin genetics, Male, Middle Aged, Osteoporosis blood, Osteoporosis physiopathology, Osteoprotegerin genetics, Pulmonary Disease, Chronic Obstructive blood, Pulmonary Disease, Chronic Obstructive physiopathology, Respiratory Function Tests, Leptin metabolism, Osteoporosis complications, Osteoporosis metabolism, Osteoprotegerin metabolism, Pulmonary Disease, Chronic Obstructive complications, Pulmonary Disease, Chronic Obstructive metabolism
- Abstract
Introduction: The role of fat-bone interactions in the pathogenesis of osteoporosis in chronic obstructive pulmonary disease (COPD) is poorly understood. Our aim was to investigate expressions of leptin and osteoprotegerin (OPG) in the adipose tissue, and their relationships to osteoporosis in patients with COPD., Methods: In 39 patients with stable COPD, bone mineral density (BMD) and body composition was assessed by Dual Energy X-Ray Absorptiometry. Serum leptin was determined by the enzyme-linked immunosorbent assay, and bone turnover markers osteocalcin and β-crosslaps by the electrochemiluminiscence immunoassays. Subcutaneous adipose tissue samples were analyzed using real-time PCR., Results: Twenty-one patients without, and 18 with osteoporosis were enrolled (35 men; age 62.2 ± 7.3years). Compared to patients without osteoporosis, those with the disease had significantly lower serum levels and adipose tissue expressions of leptin, in association with increased serum β-crosslaps (p=0.028, p=0.034, p=0.022, respectively). Log adipose tissue leptin was inversely related to serum β-crosslaps (p=0.015), and directly to serum leptin (p<0.001) and to the total, femoral, and lumbar BMD and T-score (p<0.02 for all relationships). Adipose tissue OPG expression was related to all variables of bone density except for lumbar BMD and T-score (p<0.05 for all relationships). Log adipose tissue leptin and OPG expressions predicted femoral T-score independently of age, gender and pulmonary function (p<0.001, adjusted R(2)=0.383; p=0.008, adjusted R(2)=0.301, respectively). Introducing body mass (or fat mass) index into these models eliminated independent predictive value of leptin and OPG expressions., Conclusion: Our results suggest that adipose tissue leptin and OPG expressions are related to osteoporosis in patients with COPD, and appear to act as mediators between fat mass and BMD., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
31. Increased adipose tissue expression of proinflammatory CD40, MKK4 and JNK in patients with very severe chronic obstructive pulmonary disease.
- Author
-
Tkacova R, Ukropec J, Skyba P, Ukropcova B, Pobeha P, Kurdiova T, Joppa P, Klimes I, Tkac I, and Gasperikova D
- Subjects
- Adipocytes pathology, Body Composition, Female, Gene Expression physiology, Humans, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive, Up-Regulation physiology, Adipose Tissue metabolism, CD40 Antigens metabolism, JNK Mitogen-Activated Protein Kinases metabolism, MAP Kinase Kinase 4 metabolism
- Abstract
Background: CD40, a transmembrane receptor of the tumor necrosis factor gene superfamily, is activated in response to cellular stress, including hypoxia, and orchestrates the process of inflammation via secondary messengers such as mitogen-activated protein kinase kinase 4 (MKK4) and c-Jun NH(2)-terminal kinases (JNK)., Objectives: We hypothesized that CD40, MKK4 and JNK expression is increased in the adipose tissue of patients with very severe chronic obstructive pulmonary disease (COPD)., Methods: In 20 patients with stable COPD, lung function was assessed using body plethysmography, and samples of subcutaneous adipose tissue were analyzed using real-time PCR. Body composition, including fat mass index (FMI), was assessed by bioelectrical impedance., Results: 12 patients in GOLD stage I-III (age 61.6 ± 8.6 years, 4 females, mean partial pressure of oxygen in arterial blood, PaO(2), 9.38 ± 0.21 kPa) were compared to 8 patients in GOLD stage IV (age 62.6 ± 6.3 years, all male, mean PaO(2) 7.70 ± 0.37 kPa). Compared to patients in GOLD stage I-III, patients in GOLD stage IV had lower FMI (p = 0.004), being associated with significantly higher adipose tissue expression of CD40, MKK4 and JNK [ΔΔCt: 2.55 (1.99, 4.40) vs. 1.87 (1.63, 2.23), p = 0.013; 5.19 (3.13, 5.96) vs. 2.98 (2.82, 3.86), p = 0.002; 9.01 (5.12, 11.41) vs. 4.65 (4.42, 6.26), p = 0.001, respectively]. Log-transformed CD40, MKK4 and JNK expression was significantly inversely related to PaO(2), respectively., Conclusions: Upregulation of proinflammatory CD40, MKK4 and JNK gene expression in adipose tissue in very severe COPD raises the possibility of a role of chronic systemic hypoxia in the pathogenesis of adipose tissue inflammation in COPD., (Copyright © 2010 S. Karger AG, Basel.)
- Published
- 2011
- Full Text
- View/download PDF
32. Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease.
- Author
-
Skyba P, Ukropec J, Pobeha P, Ukropcova B, Joppa P, Kurdiova T, Stroffekova K, Brusik M, Klimes I, Tkac I, Gasperikova D, and Tkacova R
- Subjects
- Aged, Antigens, CD genetics, Antigens, Differentiation, Myelomonocytic genetics, Cachexia complications, Cachexia genetics, Cachexia metabolism, Cachexia pathology, Caspase 3 genetics, Female, Gene Expression, Humans, Insulin Resistance physiology, Interleukin-6 genetics, Male, Metabolic Syndrome complications, Metabolic Syndrome genetics, Metabolic Syndrome metabolism, Middle Aged, Obesity complications, Obesity genetics, Obesity metabolism, Obesity pathology, Overweight complications, Overweight genetics, Overweight metabolism, Overweight pathology, Panniculitis complications, Panniculitis genetics, Panniculitis metabolism, Panniculitis pathology, Phenotype, Pulmonary Disease, Chronic Obstructive complications, Pulmonary Disease, Chronic Obstructive genetics, Receptors, Tumor Necrosis Factor, Type I genetics, Tumor Necrosis Factor-alpha genetics, bcl-2-Associated X Protein genetics, Adipose Tissue pathology, Inflammation pathology, Inflammation Mediators metabolism, Pulmonary Disease, Chronic Obstructive metabolism, Pulmonary Disease, Chronic Obstructive pathology
- Abstract
Potential links between metabolic derangements and adipose tissue (AT) inflammation in patients with chronic obstructive pulmonary disease (COPD) are unexplored. We investigated AT expressions of interleukin (IL)-6, tumor necrosis factor (TNF)-α, CD68 (macrophage cell surface receptor), caspase-3, and Bax, and their relationships to the metabolic phenotype in nine cachectic, 12 normal-weight, 12 overweight, and 11 obese patients with COPD (age 62.3 ± 7.2 years). With increasing body mass index, increases in AT expressions of IL-6, TNF-α, and CD68 were observed (P < .001; P = .005; P < .001, resp.), in association with reduced insulin sensitivity (P < .001). No differences were observed between cachectic and normal-weight patients in AT expressions of inflammatory or proapoptotic markers. Adipose tissue CD68 and TNF-α expressions predicted insulin sensitivity independently of known confounders (P = .005; P = .025; R(2) = 0.840). Our results suggest that AT inflammation in obese COPD patients relates to insulin resistance. Cachectic patients remain insulin sensitive, with no AT upregulation of inflammatory or proapoptotic markers.
- Published
- 2010
- Full Text
- View/download PDF
33. Adipose tissue and skeletal muscle plasticity modulates metabolic health.
- Author
-
Ukropec J, Ukropcova B, Kurdiova T, Gasperikova D, and Klimes I
- Subjects
- Adipose Tissue cytology, Adipose Tissue pathology, Animals, Exercise, Humans, Hypoxia metabolism, Hypoxia pathology, Inflammation metabolism, Inflammation pathology, Muscle, Skeletal cytology, Muscle, Skeletal pathology, Muscle, Skeletal physiology, Obesity metabolism, Obesity pathology, Adipose Tissue metabolism, Health, Muscle, Skeletal metabolism
- Abstract
Obesity, accumulation of adipose tissue, develops when energy intake exceeds energy expenditure. Adipose tissue is essential for buffering the differences between energy intake and expenditure by accumulating lipids while skeletal muscle is the energy burning machine. Here we adopted the concept that (i) adipose tissue ability to regulate the storage capacity for lipids as well as (ii) dynamic regulation of muscle and adipose tissue secretory and metabolic activity is important for maintaining the metabolic health. This might be at least in part related to tissue plasticity, a phenomenon enabling dynamic modulation of the tissue phenotype in different physiological and pathophysiological situations. Recent advances in our understanding of the complex endocrine function of adipose tissue in regulating lipid metabolism, adipogenesis, angiogenesis, extracellular matrix remodelling, inflammation and oxidative stress prompted us to review the role of tissue plasticity--dynamic changes in adipose tissue and skeletal muscle metabolic and endocrine phenotype--in determining the difference between metabolic health and disease.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.